Meeting
2021 ASCO Annual Meeting
Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.
Authors
Amer Methqal Zeidan
Yale University School of Medicine and Yale Cancer Center, New Haven, CT
Amer Methqal Zeidan , Jacqueline Suen Garcia , Pierre Fenaux , Uwe Platzbecker , Yasushi Miyazaki , Zhi-Jian Xiao , Ying Zhou , Kiran Naqvi , Steve Kye , Guillermo Garcia-Manero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT04401748
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7054)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7054
Abstract #
TPS7054
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
First Author: Michael Richard Grunwald
Poster
2018 ASCO Annual Meeting
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
First Author: Chun Yew Fong
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi